You searched for "outcome"
South-South collaboration for the treatment of avoidable blindness in Botswana
This article describes the value of South-South collaboration in the reduction of avoidable blindness. Specifically it describes a South-South collaboration between India and Botswana that evolved out of the VISION 2020 LINK between Cambridge University Hospitals, two institutions in India...Case series of toxic anterior segment syndrome
Herein we report two cases of toxic anterior segment syndrome (TASS) following uneventful cataract surgery. Both patients presented 24 hours after their uneventful operations with painless blurred vision in the operated eye. The inflammatory reaction was controlled successfully with an...Pathophysiology of diabetic macular oedema: why combination therapy may be better
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...A paradigm shift in the way we approach cataract surgery
Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...Eye Capacity: clinical need should drive ophthalmic service provision
Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...Designing ophthalmology services Part 2: How do we address the queues for a clinic?
The first of this three-part series showed how systems engineering can be used to correctly diagnose and address the causes of delays in a clinic. This second article describes how to design a more productive system that meets the new...Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...
